Nurix Therapeutics, Inc.
Company Stats
- Market Cap
- $2.5B
- as of Sep 30, 2026
- Shares Outstanding
- 103.8M
- Free Float
- 93.0%
Income Statement
- Revenue
- $84.0M
- Operating Income
- -$285.7M
- Net Income
- -$264.5M
- EBITDA
- -$276.9M
- Revenue Growth, 3Y
- 29.5%
- FCF Margin, 3Y Avg
- -254.6%
- FCF Margin, Worst Year
- -333.4%
Cash Flow
- Free Cash Flow
- -$263.5M
- FCF Yield
- -10.7%
- Owner FCF Yield
- -12.3%
Balance Sheet
- Cash & Equivalents
- $247.0M
Returns & Capital
- SBC, 3Y Avg
- $35.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $84.0M | -$263.5M | -313.7% |
| FY2024 | $54.5M | -$181.9M | -333.4% |
| FY2023 | $77.0M | -$89.8M | -116.6% |
| FY2022 | $38.6M | -$172.1M | -445.4% |
| FY2021 | $29.8M | -$90.0M | -302.6% |
Annual filing data through FY ended November 30, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 29, 2026
Theme Survey
Cybersecurity Incidents: Named Events, Wider Legal Exposure
October 7, 2026
Theme Survey
Cybersecurity Incidents: Named Breaches and Reporting Risks
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
June 8, 2026
Deals
Nurix Therapeutics to License BTK Degrader Bexobrutideg to Roche in Up to $2.3 Billion Deal
Cybersecurity Incidents: Named Events, Wider Legal Exposure
October 7, 2026
Theme Survey
Cybersecurity Incidents: Named Breaches and Reporting Risks
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
June 8, 2026
Deals
Nurix Therapeutics to License BTK Degrader Bexobrutideg to Roche in Up to $2.3 Billion Deal